Role of anthracyclines in the treatment of early breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages 4798-4808

  Gianni, Luca ^a   Norton, Larry ^a   Wolmark, Norman ^a   Suter, Thomas M ^a   Bonadonna, Gianni ^a   Hortobagyi, Gabriel N ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB; VINBLASTINE; ANTHRACYCLINE; BRIDGED COMPOUND; TAXANE; TAXOID;

ADD ON THERAPY; ADJUVANT THERAPY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY CANCER; GENETIC MARKER; HEART DISEASE; HUMAN; HYPERTENSION; HYPOKINESIA; LEUKEMIA; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME;

EID: 70350450611     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.4791     Document Type: Review

References (100)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Goldhirsch A, Wood WC, Gelber RD, et al: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144, 2007
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
4. Trudeau M, Charbonneau F, Gelmon K, et al: Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886-898, 2005
5. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
6. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1998
7. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
8. Piccart M, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer. J Clin Oncol 19:3103-3110, 2001
9. Levine M, Bramwell VH, Pritchard KI, et al: Randomised trial of intensive cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16:2651-1658, 1998
10. Levine MN, Pritchard KI, Bramwell VH, et al: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166-5170, 2005
11. Bonneterre J, Roché H, Kerbrat P, et al: Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686-2693, 2005
12. Poole CJ, Earl HM, Hiller L, et al: NEAT Investigators and the SCTBG: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851-1862, 2006
13. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991
14. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten year results. JAMA 273:542-547, 1995
15. Bonadonna G, Zambetti M, Moliterni A, et al: Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate and fluorouracil in operable breast cancer. J Clin Oncol 22:1614-1620, 2004
16. Perloff M, Norton L, Korzun AH, et al: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-crossresistant regimen: A Cancer and Leukemia Group B study. J Clin Oncol 14:1589-1598, 1996
17. Peto R: Plenary lecture. San Antonio Breast Cancer Conference December 13, 2007, San Antonio, TX. http://www.sabcs.org/EnduringMaterials/Index. asp#webcast
18. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
19. Jones S, Holmes F, O'Shaughnessy J, et al: Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: Docetaxel/ cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Trt 106:1s, 2007 (suppl 1; abstr 12)
20. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
21. Buzdar AU, Singletary SE, Valero V, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079, 2002
22. Gianni L, Baselga J, Eiermann W, et al: European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide, methotrexate and fluorouracil (CMF). J Clin Oncol 23:7s, 2005 (abstr 513)
23. Martin M, Pienkowski T, Mackey J, et al: Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
24. Roche H, Fumoleau P, Spielman M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node positive breast cancer patients: The FNCLCC PACS 01 trial. J Clin Oncol 24:5664-5671, 2006
25. De Laurentiis M: Sequential epirubicin-docetaxel-CMF regimen as adjuvant therapy of early breast cancer: Preliminary results of the Taxit-216 multicenter phase III trial. Proc Am Soc Clin Oncol 22:29a, 2003 (abstr 115)
26. Francis P, Crown J, Di Leo A, et al: Adjuvant chemotherapy with sequential or concurrent anthra-cycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100:121-133, 2008
27. Burnell M, Levine M, Chapman JA, et al: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis. Breast Cancer Res Trt 100: S22, 2006 (suppl; abstr 53)
28. Martín M, Rodríguez-Lescure A, Ruiz A, et al: GEICAM 9906 Study Investigators: Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805-814, 2008
29. Fountzilas G, Skarlos D, Dafni U, et al: Post-operative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: A randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16:1762-1771, 2005
30. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Trt 94:S5, 2005 (suppl 1; abstr 1)
31. Slamon D, Eiermann W, Robert N, et al: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: Second interim efficacy analysis. Presented at the San Antonio Breast Cancer meeting, December 2006, San Antonio, TX, December 14-17, 2006. http://www.bcirg.org/NR/rdonlyres/ eqkdodg2dy7t557o7s6uvj7ytpe6gcfg5gmh2ely6hnhh5pjlabz3nd 6jddlnao7qoikej3edohsijyiisfvp367uuc/BCIRG006+ 2nd+Interim+Analysis.pdf
32. Smith I, Procter M, Gelber RD, et al: HERA study team: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007
33. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007
34. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
35. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
36. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
37. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
38. Spielmann M, Roché H, Humblet Y, et al: 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: Results of the PACS-04 trial. Breast Cancer Res Trt 106:S19, 2007 (suppl; abstr 72)
39. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995
40. Ravdin PM, Burris HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
41. Valero V, Holmes F, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antine-oplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
42. Goldstein L, O'Neill A, Sparano J, et al: E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 24:7s, 2005 (suppl; abstr 512)
43. Eiermann W, Pienkowski T, Crown J, et al: BCIRG 005 main efficacy analysis: A phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. Proc CTRC-AACR San Antonio Breast Cancer Conference Symposium 2008, San Antonio, TX, December 10-14, 2008 (abstr 77)
44. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
45. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
46. Hudis C, Citron ML, Berry D, et al: Five year follow-up of INT C9741: Dose dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res Trt 94:S20, 2005 (suppl 1; abstr 41)
47. Moebus VJ, Lueck HJ, Thomssen C, et al: Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4+ LN): Mature results of an AGO-trial. Breast Cancer Res Trt 100:S20, 2006 (suppl; abstr 43)
48. Moebus V, Lueck H, Thomssen C, et al: The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 25:20s, 2007 (suppl; abstr 569)
49. Muss HB, Thor AD, Berry DA, et al: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
50. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008
51. Dhesy-Thind B, Pritchard KI, Messersmith H, et al: HER2/neu in systemic therapy for women with breast cancer: A systematic review. Breast Cancer Res Trt 109:209-229, 2008
52. Pritchard KI, Messersmith H, Elavathil L, et al: HER2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736-744, 2008
53. Pegram MD, Finn RS, Arzoo K, et al: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
54. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Trt 24:85-95, 1992
55. Orr MS, O'Connor PM, Kohn KW: Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. J Natl Cancer Inst 92:987-994, 2000
56. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001
57. Bartlett JM, Munro A, Cameron DA, et al: Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 25:4423-4430, 2008
58. Di Leo A, Gancberg D, Larsimont D, et al: HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in nodepositive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116, 2002
59. Del Mastro L, Bruzzi P, Nicolò G, et al: HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer 93:7-14, 2005
60. Hayes DF, Thor AD, Dressler LG, et al: Cancer and Leukemia Group B (CALGB) Investigators: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007
61. Witters LM, Santala SM, Engle L, et al: Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Am J Clin Oncol 26:50-54, 2003
62. Azambuja E, Durbecq V, Rosa DD, et al: HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 19:223-232, 2008
63. Ciardiello F, Caputo R, Pomatico, G, et al: Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer 85:710-715, 2000
64. Yu D, Liu B, Tan M, et al: Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13:1359-1365, 1996
65. Yu D, Jing T, Liu B, et al: Overexpression of erbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2:581-591, 1998
66. Walker RA, Bartlett JMS, Dowsett M, et al: HER2 testing in the UK: Further update to recommendations. J Clin Pathol 61:818-824, 2008
67. Jarvinen TAH, Liu ET: Simultaneous amplifi-cation of HER-2 (ERBB2) and topoisomerase IIα (TOP2A) genes: Molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6:579-602, 2006
68. Järvinen TAH, Tanner M, Rantanen V, et al: Amplification and deletion of topoisomerase IIα associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847, 2000
69. O'Malley FP, Chia S, Tu D, et al: Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). J Clin Oncol 24:11s, 2006 (abstr 533)
70. O'Malley FP, Chia S, Tu D, et al: Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). Breast Cancer Res Trt 100:S18, 2006 (abstr 38)
71. Slamon DJ, Mackey J, Robert N, et al: Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. Breast Cancer Res Trt 106:1s, 2007(suppl 1; abstr 13)
72. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifi-cations and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490, 2005
73. Nielsen KV, Ejlertsen B, Møller S, et al: The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 47:725-734, 2008
74. Tanner M, Isola J, Wiklund T, et al: Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/ neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24:2428-2436, 2006
75. Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al: Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Trt 106:181-189, 2007
76. Schindlbeck C, Janni W, Shabani N, et al: Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracycline based therapy: Influenced by the HER2- and topoisomerase IIalpha-status of the primary tumor? J Cancer Res Clin Oncol 131:539-546, 2005
77. Durbecq V, Paesmans M, Cardoso F, et al: Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Molecular Cancer Therapeutics 3:1207-1214, 2004
78. Cardoso F, Durbecq V, Larsimont D, et al: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 24:201-209, 2004
79. Park K, Kim J, Lim S, et al: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39:631-634, 2003
80. Martin-Richard M, Munoz M, Albanell J, et al: Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 66:388-394, 2004
81. Coon JS, Marcus E, Gupta-Burt S, et al: Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061-1067, 2002
82. Bofin AM, Ytterhus B, Hagmar BM: TO2A and HER-2 gene amplification in fine needle aspirates of breast carcinomas. Cytopathol 14:314-319, 2003
83. Olsen KE, Knudsen H, Rasmussen BB, et al: Danish Breast Cancer Co-operative Group: Amplifi-cation of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43:35-42, 2004
84. Järvinen TA, Tanner M, Bärlund M, et al: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150, 1999
85. Minotti G, Menna P, Salvatorelli E, et al: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229, 2004
86. Mueller RE, Parkes RK, Andrulis I, et al: Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 39:288-297, 2004
87. Di Leo A, Gancberg D, Larsimont D, et al: HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12:1081-1089, 2001
88. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
89. Jones LW, Haykowsky MJ, Swartz JJ, et al: Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50:1435-1441, 2007
90. Steinherz LJ, Steinherz PG, Tan CT, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
91. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia of childhood. N Engl J Med 324:808-815, 1991
92. Goorin AM, Chauvenet AR, Perez-Atayde AR, et al: Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116:144-147, 1990
93. Zambetti M, Moliterni A, Materazzo C, et al: Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19:37-43, 2001
94. Ganz PA, Hussey MA, Moinpour CM, et al: Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897. J Clin Oncol 26:1223-1230, 2008
95. Eskens FA, Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42:3127-3139, 2006
96. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
97. Suter TM, Cook-Bruns N, Barton C: Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13:173-183, 2004
98. Dang C, Fornier M, Sugarman S, et al: The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 26:1216-1222, 2008
99. McArthur HL, Rugo H, Paulson M, et al: Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Breast Cancer Res Trt 106:S147, 2007 (suppl 1; abstr 3065)
100. Perez EA, Koehler M, Byrne J, et al: Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83:679-686, 2008